The Intellectual Property and Science business of Thomson Reuters has announced the release of Biosimilars: A Global Perspective of a New Market – Opportunities, Threats and Critical Strategies 2014. The new report, compiled by Thomson Reuters BioWorld, the premier biopharmaceutical news service, provides critical insights for companies and regions interested in maintaining a strong position and moving ahead of the competition in the biosimilars space.
It is rare to see a new business segment emerge in any market, but this is what is happening within the biopharmaceutical development industry. There are currently 700 follow-on biologics therapies moving through pipelines with many already approved and 245 biopharma companies and institutes developing or already marketing follow-on biologics in markets throughout the world. Biosimilars are expected to account for approximately one quarter of the $100 billion worth of sales stemming from off-patent biologics by the end of the decade.
South Korea is a notable standout in the race for global leadership in this space and India anticipates biosimilars becoming the most important economic and therapeutic component of its already robust biopharma industry.
The study - the culmination of BioWorld's research combined with key data and insights gathered from Cortellis Competitive Intelligence, Cortellis Regulatory Intelligence, Newport Premium and input from Thomson Reuters Life Sciences Professional Services - provides a comprehensive view of this emerging market with a listing of approved biosimilars, company and deal terms for more than 100 alliances, and an examination of global markets.
For those interested in learning more about this emerging market, Thomson Reuters will be hosting a webinar on biosimilars on September 30 at 11 A.M. ET. Click here to register.
